Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288.

Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M, Weis J, Morag O, Lindviksmoen Astrup G, Tomaszewksi KA, Pogoda K, Sinai P, Sprangers M, Aaronson N, Velikova G, Greimel E, Arraras J, Bottomley A; EORTC Quality of Life Group and Breast Cancer Group.

Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36026-9. doi: 10.1016/j.annonc.2020.02.001. [Epub ahead of print] No abstract available.

PMID:
32089397
2.

Patient understanding of the aim and duration of treatment during the consent process.

Kumaran G, Razzaq M, Velikova G, Papaxoinis G, Corker S, Fox F, Peters R, Kamposioras K.

Ann Oncol. 2019 Jul;30 Suppl 4:iv43. doi: 10.1093/annonc/mdz155.157. Epub 2019 Dec 4. No abstract available.

PMID:
32085162
3.

Technology is the future, but who are we leaving behind?

Nicklin E, Velikova G, Boele F.

Lancet Oncol. 2020 Jan;21(1):29. doi: 10.1016/S1470-2045(19)30640-0. Epub 2020 Jan 2. No abstract available.

PMID:
32007212
4.

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N, Dorme L, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium.

Lancet Oncol. 2020 Feb;21(2):e83-e96. doi: 10.1016/S1470-2045(19)30790-9. Review.

PMID:
32007209
5.

An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45.

Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M, Weis J, Morag O, Lindviksmoen Astrup G, Tomaszweksi KA, Pogoda K, Sinai P, Sprangers M, Aaronson N, Velikova G, Greimel E, Arraras J, Bottomley A; EORTC Quality of Life Group and Breast Cancer Group.

Ann Oncol. 2020 Feb;31(2):283-288. doi: 10.1016/j.annonc.2019.10.027. Epub 2019 Dec 18. Erratum in: Ann Oncol. 2020 Feb 20;:.

PMID:
31959345
6.

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.

Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M, Piccart M, Van Tienhoven G, Mansel R, Wildiers H, Bottomley A; EORTC and EORTC Breast Cancer Group.

Eur J Cancer. 2020 Jan;125:69-82. doi: 10.1016/j.ejca.2019.10.031. Epub 2019 Dec 12.

7.

Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review.

Mierzynska J, Piccinin C, Pe M, Martinelli F, Gotay C, Coens C, Mauer M, Eggermont A, Groenvold M, Bjordal K, Reijneveld J, Velikova G, Bottomley A.

Lancet Oncol. 2019 Dec;20(12):e685-e698. doi: 10.1016/S1470-2045(19)30656-4. Review.

PMID:
31797795
8.

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.

Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G, Banks RE, Brown J, Velikova G, Waddell T, Fife K, Nathan PD, Larkin J, Powles T, Brown SR, Vasudev NS.

BMC Cancer. 2019 Nov 14;19(1):1102. doi: 10.1186/s12885-019-6273-1.

9.

Cancer as a chronic illness: support needs and experiences.

Boele F, Harley C, Pini S, Kenyon L, Daffu-O'Reilly A, Velikova G.

BMJ Support Palliat Care. 2019 Sep 19. pii: bmjspcare-2019-001882. doi: 10.1136/bmjspcare-2019-001882. [Epub ahead of print]

PMID:
31537579
10.

Net Pain Relief After Palliative Radiation Therapy for Painful Bone Metastases: A Useful Measure to Reflect Response Duration? A Further Analysis of the Dutch Bone Metastasis Study.

Spencer K, Velikova G, Henry A, Westhoff P, Hall PT, van der Linden YM.

Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):559-566. doi: 10.1016/j.ijrobp.2019.07.009. Epub 2019 Jul 22.

11.

Assessing the quality and communicative aspects of patient decision aids for early-stage breast cancer treatment: a systematic review.

Vromans R, Tenfelde K, Pauws S, van Eenbergen M, Mares-Engelberts I, Velikova G, van de Poll-Franse L, Krahmer E.

Breast Cancer Res Treat. 2019 Nov;178(1):1-15. doi: 10.1007/s10549-019-05351-4. Epub 2019 Jul 24. Review.

12.

Developing a real-time electronic symptom monitoring system for patients after discharge following cancer-related surgery.

Avery KNL, Richards HS, Portal A, Reed T, Harding R, Carter R, Bamforth L, Absolom K, O'Connell Francischetto E, Velikova G, Blazeby JM.

BMC Cancer. 2019 May 17;19(1):463. doi: 10.1186/s12885-019-5657-6.

13.
14.

Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials.

Kyte D, Retzer A, Ahmed K, Keeley T, Armes J, Brown JM, Calman L, Gavin A, Glaser AW, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Efficace F, Mercieca-Bebber R, King MT, Turner G, Calvert M.

J Natl Cancer Inst. 2019 Nov 1;111(11):1170-1178. doi: 10.1093/jnci/djz038.

15.

Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution.

Liu Y, Siejka-Zielińska P, Velikova G, Bi Y, Yuan F, Tomkova M, Bai C, Chen L, Schuster-Böckler B, Song CX.

Nat Biotechnol. 2019 Apr;37(4):424-429. doi: 10.1038/s41587-019-0041-2. Epub 2019 Feb 25.

PMID:
30804537
16.

Online tool for monitoring adverse events in patients with cancer during treatment (eRAPID): field testing in a clinical setting.

Warrington L, Absolom K, Holch P, Gibson A, Clayton B, Velikova G.

BMJ Open. 2019 Feb 1;9(1):e025185. doi: 10.1136/bmjopen-2018-025185.

17.

Are quality of life outcomes comparable following stereotactic radiotherapy and minimally invasive surgery for stage I lung cancer patients?

Pompili C, Absolom K, Franks K, Velikova G.

J Thorac Dis. 2018 Dec;10(12):7055-7063. doi: 10.21037/jtd.2018.11.89. Review.

18.

Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.

Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E, Wagland R, Kind P, Donnelly DW, Butcher H, Catto JWF, Cross W, Mason M, Sharp L, Weller D, Velikova G, McCaughan E, Mottram R, Allen M, Kearney T, McSorley O, Huws DW, Brewster DH, McNair E, Gavin A, Glaser AW.

Lancet Oncol. 2019 Mar;20(3):436-447. doi: 10.1016/S1470-2045(18)30780-0. Epub 2019 Jan 31.

19.

Electronic Systems for Patients to Report and Manage Side Effects of Cancer Treatment: Systematic Review.

Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, Velikova G.

J Med Internet Res. 2019 Jan 24;21(1):e10875. doi: 10.2196/10875.

20.

Long-term issues and supportive care needs of adolescent and young adult childhood brain tumour survivors and their caregivers: A systematic review.

Nicklin E, Velikova G, Hulme C, Rodriguez Lopez R, Glaser A, Kwok-Williams M, Boele F.

Psychooncology. 2019 Mar;28(3):477-487. doi: 10.1002/pon.4989. Epub 2019 Feb 1.

21.

Digitally enabled patient-reported outcome measures in cancer care.

Lindner OC, Velikova G, Stark DP.

Lancet Oncol. 2019 Jan;20(1):e2. doi: 10.1016/S1470-2045(18)30894-5. No abstract available.

PMID:
30614473
22.

Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.

Musoro JZ, Bottomley A, Coens C, Eggermont AM, King MT, Cocks K, Sprangers MA, Groenvold M, Velikova G, Flechtner HH, Brandberg Y; EORTC Melanoma Group and EORTC Quality of Life Group.

Eur J Cancer. 2018 Nov;104:169-181. doi: 10.1016/j.ejca.2018.09.005. Epub 2018 Oct 22.

PMID:
30359910
23.

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.

Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, Clarke J, Kunkler IH, Russell NS; MRC SUPREMO trial UK investigators.

Lancet Oncol. 2018 Nov;19(11):1516-1529. doi: 10.1016/S1470-2045(18)30515-1. Epub 2018 Oct 15. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668.

24.

Implementation of Patient-Reported Outcomes in Routine Medical Care.

Basch E, Barbera L, Kerrigan CL, Velikova G.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:122-134. doi: 10.1200/EDBK_200383. Review.

25.

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL).

Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2.

26.

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C.

Clin Trials. 2018 Dec;15(6):624-630. doi: 10.1177/1740774518795637. Epub 2018 Aug 24.

27.

EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC).

Pompili C, Koller M, Velikova G, Franks K, Absolom K, Callister M, Robson J, Imperatori A, Brunelli A.

Lung Cancer. 2018 Sep;123:149-154. doi: 10.1016/j.lungcan.2018.07.021. Epub 2018 Jul 17.

28.

Taking patient reported outcomes centre stage in cancer research - why has it taken so long?

Selby P, Velikova G.

Res Involv Engagem. 2018 Jul 19;4:25. doi: 10.1186/s40900-018-0109-z. eCollection 2018.

29.

eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy.

Holch P, Pini S, Henry AM, Davidson S, Routledge J, Brown J, Absolom K, Gilbert A, Franks K, Hulme C, Morris C, Velikova G; eRAPID radiotherapy work group.

Pilot Feasibility Stud. 2018 Jun 5;4:110. doi: 10.1186/s40814-018-0304-6. eCollection 2018.

30.

The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.

Petersen MA, Aaronson NK, Arraras JI, Chie WC, Conroy T, Costantini A, Dirven L, Fayers P, Gamper EM, Giesinger JM, Habets EJJ, Hammerlid E, Helbostad J, Hjermstad MJ, Holzner B, Johnson C, Kemmler G, King MT, Kaasa S, Loge JH, Reijneveld JC, Singer S, Taphoorn MJB, Thamsborg LH, Tomaszewski KA, Velikova G, Verdonck-de Leeuw IM, Young T, Groenvold M; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group.

Eur J Cancer. 2018 Sep;100:8-16. doi: 10.1016/j.ejca.2018.04.016. Epub 2018 Jun 21.

31.

Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.

Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ.

Value Health. 2018 Jun;21(6):742-747. doi: 10.1016/j.jval.2017.09.009. Epub 2017 Nov 7.

32.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

33.

Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items.

Taarnhøj GA, Kennedy FR, Absolom KL, Bæksted C, Vogelius IR, Johansen C, Velikova G, Pappot H.

J Pain Symptom Manage. 2018 Sep;56(3):421-429. doi: 10.1016/j.jpainsymman.2018.05.017. Epub 2018 May 25.

34.

Developing a complex intervention to support timely engagement with palliative care for patients with advanced cancer in primary and secondary care in the UK: a study protocol.

Hackett J, Bekker H, Bennett MI, Carder P, Gallagher J, Henry C, Kite S, Taylor S, Velikova G, Ziegler L.

BMJ Open. 2018 May 14;8(5):e022835. doi: 10.1136/bmjopen-2018-022835.

35.

Patients reported outcomes in thoracic surgery.

Pompili C, Absolom K, Velikova G, Backhus L.

J Thorac Dis. 2018 Feb;10(2):703-706. doi: 10.21037/jtd.2018.01.140. No abstract available.

36.

Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.

Retzer A, Keeley T, Ahmed K, Armes J, Brown JM, Calman L, Copland C, Efficace F, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M, Kyte D.

BMJ Open. 2018 Feb 3;8(2):e017282. doi: 10.1136/bmjopen-2017-017282.

37.

Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.

Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT; the SPIRIT-PRO Group, Hunn A, Bottomley A, Regnault A, Chan AW, Ells C, O'Connor D, Revicki D, Patrick D, Altman D, Basch E, Velikova G, Price G, Draper H, Blazeby J, Scott J, Coast J, Norquist J, Brown J, Haywood K, Johnson LL, Campbell L, Frank L, von Hildebrand M, Brundage M, Palmer M, Kluetz P, Stephens R, Golub RM, Mitchell S, Groves T.

JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.

38.

Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol.

Musoro ZJ, Hamel JF, Ediebah DE, Cocks K, King MT, Groenvold M, Sprangers MAG, Brandberg Y, Velikova G, Maringwa J, Flechtner HH, Bottomley A, Coens C; EORTC Quality of Life Group.

BMJ Open. 2018 Jan 10;8(1):e019117. doi: 10.1136/bmjopen-2017-019117.

39.

Patient reported outcomes following video assisted thoracoscopic (VATS) resection or stereotactic ablative body radiotherapy (SABR) for treatment of non-small cell lung cancer: protocol for an observational pilot study (LiLAC).

Pompili C, Franks KN, Brunelli A, Hussain YS, Holch P, Callister ME, Robson JM, Papagiannopoulos K, Velikova G.

J Thorac Dis. 2017 Aug;9(8):2703-2713. doi: 10.21037/jtd.2017.07.35.

40.

Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment.

Holch P, Warrington L, Bamforth LCA, Keding A, Ziegler LE, Absolom K, Hector C, Harley C, Johnson O, Hall G, Morris C, Velikova G.

Ann Oncol. 2017 Sep 1;28(9):2305-2311. doi: 10.1093/annonc/mdx317.

41.

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.

Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators.

Lancet Oncol. 2017 Jul;18(7):929-945. doi: 10.1016/S1470-2045(17)30404-7. Epub 2017 Jun 7.

42.

Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID): a randomised controlled trial in systemic cancer treatment.

Absolom K, Holch P, Warrington L, Samy F, Hulme C, Hewison J, Morris C, Bamforth L, Conner M, Brown J, Velikova G; eRAPID systemic treatment work group.

BMC Cancer. 2017 May 8;17(1):318. doi: 10.1186/s12885-017-3303-8.

43.

Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.

Berntsen S, Aaronson NK, Buffart L, Börjeson S, Demmelmaier I, Hellbom M, Hojman P, Igelström H, Johansson B, Pingel R, Raastad T, Velikova G, Åsenlöf P, Nordin K.

BMC Cancer. 2017 Mar 27;17(1):218. doi: 10.1186/s12885-017-3197-5.

44.

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.

Stark DP, Cook A, Brown JM, Brundage MD, Embleton AC, Kaplan RS, Raja FA, Swart AMW, Velikova G, Qian W, Ledermann JA.

Cancer. 2017 Jul 15;123(14):2752-2761. doi: 10.1002/cncr.30657. Epub 2017 Mar 24.

45.

Erratum to: Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.

Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DSJ, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT.

Qual Life Res. 2017 Aug;26(8):2247-2248. doi: 10.1007/s11136-017-1546-0. No abstract available.

PMID:
28337638
46.

Observational study of the development and evaluation of a fertility preservation patient decision aid for teenage and adult women diagnosed with cancer: the Cancer, Fertility and Me research protocol.

Jones GL, Hughes J, Mahmoodi N, Greenfield D, Brauten-Smith G, Skull J, Gath J, Yeomanson D, Baskind E, Snowden JA, Jacques RM, Velikova G, Collins K, Stark D, Phillips R, Lane S, Bekker HL; (On behalf of the Cancer, Fertility and Me research team).

BMJ Open. 2017 Mar 13;7(3):e013219. doi: 10.1136/bmjopen-2016-013219.

47.

Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials.

Holch P, Henry AM, Davidson S, Gilbert A, Routledge J, Shearsmith L, Franks K, Ingleson E, Albutt A, Velikova G.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):495-510. doi: 10.1016/j.ijrobp.2016.11.008. Epub 2016 Nov 18. Review.

48.

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).

Hall PS, Lord SR, Collinson M, Marshall H, Jones M, Lowe C, Howard H, Swinson D, Velikova G, Anthoney A, Roy R, Dent J, Cheeseman S, Last K, Seymour MT.

Br J Cancer. 2017 Feb 14;116(4):472-478. doi: 10.1038/bjc.2016.442. Epub 2017 Jan 17.

49.

Poor preoperative patient-reported quality of life is associated with complications following pulmonary lobectomy for lung cancer.

Pompili C, Velikova G, White J, Callister M, Robson J, Dixon S, Franks K, Brunelli A.

Eur J Cardiothorac Surg. 2017 Mar 1;51(3):526-531. doi: 10.1093/ejcts/ezw363.

50.

Health-related quality of life in cancer survivorship: Predictive power of the Social Difficulties Inventory.

Ashley L, Velikova G, Downing A, Morris E, Wright P.

Psychooncology. 2017 Nov;26(11):1994-1997. doi: 10.1002/pon.4368. Epub 2017 Feb 27. No abstract available.

Supplemental Content

Loading ...
Support Center